Alzheimer’s disease (AD) is correlated with the aggregation of tau protein, which also deposits in several other neurodegenerative diseases. The AD-specific tau deposit has recently been identified and recapitulated in animal models by our laboratory, but the properties of such AD-specific tau deposits are still largely unclear. This project is aimed at characterizing such AD-specific tau deposits, with the hope of developing an AD diagnosis method and potentially new treatment approaches.
See what research we fund.
- Zhuohao He, PhDUniversity of Pennsylvania (Philadelphia, PA)ID:A2018802SJuly 1, 2018 to June 30, 2021Alzheimer's DiseaseStandard$300,000
- Karl Wahlin, PhDUniversity of California, San Diego (La Jolla, CA)
Macular degenerative disease affects millions worldwide and models to study the condition in humans are generally lacking. We have developed human disease-based stem cell lines (created from adult stem cells) that can be readily converted into retinal pigment epithelium (RPE) in order to study the disease process in the laboratory. Unique to this project, we have also designed a fluorescent protein reporter that will allow us to study the temporal dynamics of RPE cell dystrophy, thus allowing the systematic optimization of drug screening aimed at reducing protein deposits typical of AMD.ID:M2018175July 1, 2018 to June 30, 2020Macular DegenerationStandard$160,000
Recipient of the Carolyn K. McGillvray Award for Macular Degeneration Research
- Monica Jablonski, PhDThe University of Tennessee Health Science Center (Memphis, TN)
Millions of people are affected by glaucoma and some lose their vision due to this disease. To develop new drugs to treat glaucoma or to understand why glaucoma causes vision loss, it is important to have accurate models of the disease. Unfortunately, there are not enough models available that truly reflect the human disease. We hope to change that. In our study, we will identify and characterize new glaucoma models that share the disease phenotypes of humans. These models will be a very useful resource for all vision scientists.ID:G2018116July 1, 2018 to June 30, 2020GlaucomaStandard$150,000
- Magali Saint-Geniez, PhDThe Schepens Eye Research Institute, Harvard Medical School (Boston, MA)
Vision loss in AMD is caused by the dysfunction and loss of the retinal pigment epithelium (RPE), a pigmented layer of cells which support the photosensitive photoreceptors. RPE health and protective functions depend on their metabolism, the highly regulated process controlling energy production and by-products detoxification. Here we will study a novel pathogenic mechanism responsible for impaired RPE metabolism and progression to the advanced neovascular form of AMD.ID:M2018064July 1, 2018 to June 30, 2020Macular DegenerationStandard$160,000
- Wei Cao, PhDBaylor College of Medicine (Houston, TX)
Alzheimer’s disease (AD) is a devastating disease with no cure. Often, the brains of AD patients have ongoing inflammation that fuels the disease. This project will study a new family of cytokines (ie, proteins regulating the immune system) which we recently detected in AD brains. Our goal is to obtain knowledge about how inflammation worsens AD, and also to identify targets for effective treatments.ID:A2018377SCollaborators:Hui Zheng, PhDJuly 1, 2018 to June 30, 2021Alzheimer's DiseaseStandard$300,000
- Yingjun Zhao, PhDSanford Burnham Prebys Medical Discovery Institute (La Jolla, CA)
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder worldwide and has devastating effects on memory and brain function in affected individuals. Although the exact causes that accelerate memory loss are not known, it is likely that a toxic protein amyloid beta (Aβ) plays a vital role in disrupting communication junctions in the brain as AD progresses.ID:A2018214FCollaborators:Robert Rissman, PhDMentors:Huaxi Xu, PhDJuly 1, 2018 to June 30, 2020Alzheimer's DiseasePostdoctoral Fellowship$150,000
This grant is made possible in part by the support of the J. T. Tai Foundation.
- Jill M. Goldstein, PhDMassachusetts General Hospital and Harvard Medical School (Boston, MA)
This project will support the launching of a comprehensive effort (integrating clinical, physiological and brain biology traits) to identify in early midlife biomarkers for Alzheimer’s disease risk informed by sex differences in brain aging and memory decline. This is one of the first projects to comprehensively assess multiple predicted biomarkers for Alzheimer’s risk in middle age and relate them to brain scans, physiology, genetics, and clinical data with a specific focus on incorporating differences between men and women in Alzheimer’s development.ID:CA2018607March 30, 2018 to March 29, 2020Alzheimer's DiseaseStandard$1,112,000
- Ann-Charlotte Granholm-Bentley, PhD, DDSUniversity of Denver (Denver, Colorado)
The focus of this special project is to develop a strong collaborate network between six different research groups focused on providing much-needed information about the Down syndrome population, of which as many as 80 percent have Alzheimer’s pathology by the time they are in their 50s and 60s. Although there are many centers and researchers that focus on Alzheimer’s in the general population, few of them focus on people with Down syndrome. The information generated by our project will be of great help to those with Down syndrome and those with Alzheimer’s disease.ID:CA2018010Co-principal Investigators:Elizabeth Head, PhD; Elliott Mufson, PhDNovember 1, 2017 to October 31, 2022Alzheimer's DiseaseStandard$435,050
- Peter Tessier, PhDUniversity of Michigan (Ann Arbor, MI)
Alzheimer’s disease (AD) is linked to proteins that misbehave and stick together into protein particles that are toxic to brain cells. Early detection of this dreaded disease requires the generation of imaging molecules that can enter the brain and selectively tag the toxic protein particles in different parts of the brain. We aim to use an innovative design and evolution method for generating imaging probes specific for particles of one of the most harmful Alzheimer’s proteins (tau). We will use these novel probes to image toxic tau protein particles in the brains of mice used as models of AD, with the long-term goal of translating this technology to humans for early and accurate disease detection.ID:A2017395SSeptember 1, 2017 to August 31, 2020Alzheimer's DiseaseStandard$300,000
- Ephraim F. Trakhtenberg, PhDUniversity of Connecticut Health Center (Farmington, CT)
The biological molecular mechanisms controlling the growth of connections in the central nervous system (CNS) are still poorly understood. The inability of the eye to regenerate such connections to the brain is the key reason why vision is lost from optic nerve damage, which can happen in a disease such as glaucoma, cannot be restored. We propose to identify novel biological regulators of the intrinsic ability of the retinal cells to regrow such connections between the eye and the brain. These studies could lead to the development of therapeutics for restoring simple visual abilities to those who became blind due to angle-closure glaucoma, and possibly other types of glaucoma.ID:G2017204July 1, 2017 to June 30, 2019GlaucomaStandard$150,000